Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Three-Period, Three-Way, Randomized, Open-Label, Single-Dose, Cross-Over, Comparative Bioavailability Study of Dihydroergotamine Mesylate (DHE) Administered by I123 Precision Olfactory Delivery (PODTM) Device Nasal Spray, DHE for Injection (Intravenous), and Migranal Nasal Spray in Healthy Adult Subjects

Trial Profile

A Phase I, Three-Period, Three-Way, Randomized, Open-Label, Single-Dose, Cross-Over, Comparative Bioavailability Study of Dihydroergotamine Mesylate (DHE) Administered by I123 Precision Olfactory Delivery (PODTM) Device Nasal Spray, DHE for Injection (Intravenous), and Migranal Nasal Spray in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jan 2019

At a glance

  • Drugs Dihydroergotamine mesilate (Primary) ; Dihydroergotamine mesilate (Primary)
  • Indications Migraine
  • Focus Pharmacokinetics; Proof of concept
  • Acronyms STOP 101
  • Sponsors Impel NeuroPharma
  • Most Recent Events

    • 19 Jan 2019 Results published in the Headache
    • 01 Jul 2018 Results (n=28) presented at the 60th Annual Scientific Meeting of the American Headache Society.
    • 07 Feb 2018 According to an Impel NeuroPharma media release, the company is planning data readouts in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top